Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 16/20 | 0.43 |
| ▸ | PPARA | Q07869 | 15/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4853344 | 0.89 | PPARG (0.43) | PPARGPPARAFFAR1DRD2HTR2A | |
| SCHEMBL4034983 | 0.85 | KDR (0.53) | KDRPPARGPPARAFFAR1ALDH1A1 | |
| SCHEMBL4034034 | 0.83 | KDR (0.65) | KDRPPARGPPARAFFAR1 | |
| SCHEMBL4030472 | 0.82 | PPARG (0.42) | PPARGPPARAFFAR1DRD2HTR2A | |
| SCHEMBL4034804 | 0.81 | GABRA5 (0.46) | PPARGPPARADRD2HTR2AALDH1A1 | |
| SCHEMBL4851038 | 0.81 | PPARG (0.50) | KDRPPARGPPARAFFAR1DRD2 | |
| SCHEMBL4850712 | 0.80 | KDR (0.38) | KDRPPARGPPARAFFAR1DRD2 | |
| SCHEMBL4850977 | 0.80 | KDR (0.71) | KDRPPARGPPARAFFAR1 | |
| SCHEMBL4850848 | 0.80 | PPARG (0.58) | KDRPPARGPPARAALDH1A1 | |
| SCHEMBL4035637 | 0.80 | PPARG (0.62) | KDRPPARGPPARAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1357115-B1 | ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2009-06-17 | — | — | EP | disclosed |
| US-7241785-B2 | Five-membered heterocyclic alkanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-10 | — | — | US | disclosed |
| US-7238716-B2 | Alkanoic acid derivatives process for their production and use thereof | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2007-07-03 | — | — | US | disclosed |
| US-7179823-B1 | 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-20 | — | — | US | disclosed |
| EP-1457490-A1 | 5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity | Takeda Chemical Industries, Ltd. (JP) | 2004-09-15 | — | — | EP | disclosed |
| EP-1228067-B1 | 5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-20040063775-A1 | Five-membered heterocyclic alkanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20040058965-A1 | Alkanoic acid derivatives process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1394154-A1 | FIVE-MEMBERED HETEROCYCLIC ALKANOIC ACID DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
| EP-1357115-A1 | ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-10-29 | — | — | EP | disclosed |
| EP-1228067-A1 | 5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGYLCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001038325-A1 | 5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058965-A1 | Alkanoic acid derivatives process for their production and use thereof | GPR119, ACOX1, ALK | KDR 1328/4885PPARG 593/4885PPARA 156/4885 |
| US-20040063775-A1 | Five-membered heterocyclic alkanoic acid derivative | SLC5A1, AHR, ALOX5 | KDR 2417/4885PPARG 433/4885PPARA 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.